Medable’s New Intelligent Automation Capabilities Cut Clinical Trial Technology Deployment Timelines By 50%
Digital Health Global
JANUARY 8, 2024
A Tufts Center for the Study of Drug Development study shows that, on average, decentralized trials can achieve net financial benefits from five to 13 times for Phase II and Phase III trials, equating to roughly $10 million ROI and $39 million ROI respectively. Medable, which ranked in the top 8% of software companies on the 2023 Inc.
88 
Let's personalize your content